Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cardiovascular outcome trials (CVOTs) suggest glucagon-like peptide 1 receptor agonists (GLP-1RAs) provide greater cardiovascular (CV) benefits in Asian compared with White individuals. PURPOSE: Compare CV efficacy of GLP-1RAs between Asian and White individuals. DATA SOURCES: Systematic review of PubMed and ClinicalTrials.gov (1 January 2015 to 1 November 2024). STUDY SELECTION: Randomized placebo-controlled CVOTs of GLP-1RAs. Risk of bias was assessed (RoB 2). DATA EXTRACTION: Ethnicity-specific hazard ratios (HRs) for major adverse cardiovascular events (MACE). DATA SYNTHESIS: Random-effects meta-analyses per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines included eight trials (5,909 Asian individuals, 55,855 White individuals). GLP-1RA–associated MACE HR was 0.69 (95% CI 0.58, 0.83) in Asian people and 0.85 (95% CI 0.79, 0.91) in White people (Pinteraction = 0.045). Absolute MACE risk reduction was 2.9% (95% CI 1.5, 4.2) in Asian people versus 1.4% (0.9, 1.9) in White people. LIMITATIONS: Lack of individual patient-level data precluded detailed subclassification of the Asian group. CONCLUSIONS: GLP-1RAs may offer greater MACE reductions in Asian compared with White individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Self-citationEffects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Self-citationSattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599
Self-citationCardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Self-citationRuff, C. T., Baron, M., Im, K., O’Donoghue, M. L., Fiedorek, F. T., & Sabatine, M. S. (2022) · Nature Medicine · doi:10.1038/s41591-021-01584-3 · Cited by 102
Research works printed but not linked: 11
- Sattar, 2015, Type 2 diabetes in migrant south Asians: mechanisms, mitigation, and management, Lancet Diabetes Endocrinol, 3, 1004, 10.1016/S2213-8587(15)00326-5 · DOI · Paper page
- Lee, 2021, Meta-analyses of results from randomized outcome trials comparing cardiovascular effects of SGLT2is and GLP-1RAs in Asian versus White patients with and without type 2 diabetes, Diabetes Care, 44, 1236, 10.2337/dc20-3007 · DOI
- Kang, 2019, Asian subpopulations may exhibit greater cardiovascular benefit from long-acting glucagon-like peptide 1 receptor agonists: a meta-analysis of cardiovascular outcome trials, Diabetes Metab J, 43, 410, 10.4093/dmj.2018.0070 · DOI · Paper page
- Lee, 2022, Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a meta-analysis with the FREEDOM cardiovascular outcomes trial, Diabetes Metab Syndr, 16, 102382, 10.1016/j.dsx.2021.102382 · DOI · Paper page
- Holman, 2017, Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes, N Engl J Med, 377, 1228, 10.1056/NEJMoa1612917 · DOI · Paper page
- Gerstein, 2019, Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial, Lancet, 394, 121, 10.1016/S0140-6736(19)31149-3 · DOI · Paper page
- Husain, 2019, Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med, 381, 841, 10.1056/NEJMoa1901118 · DOI · Paper page
- Gerstein, 2023, Exploring the relationship between efpeglenatide dose and cardiovascular outcomes in type 2 diabetes: insights from the AMPLITUDE-O trial, Circulation, 147, 1004, 10.1161/CIRCULATIONAHA.122.063716 · DOI
- Smart, 2017, The under-representation of minority ethnic groups in UK medical research, Ethn Health, 22, 65, 10.1080/13557858.2016.1182126 · DOI · Paper page
- Lear, 2007, Visceral adipose tissue accumulation differs according to ethnic background: results of the Multicultural Community Health Assessment Trial (M-CHAT), Am J Clin Nutr, 86, 353, 10.1093/ajcn/86.2.353 · DOI · Paper page
- Wang, 2020, Disparities in gastric emptying and postprandial glycaemia between Han Chinese and Caucasians with type 2 diabetes, Diabetes Res Clin Pract, 159, 107951, 10.1016/j.diabres.2019.107951 · DOI · Paper page
Cited by
Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes
Nicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Miller, D., Nauck, M. A., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505928 · Cited by 223
Self-citation10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s010 · Cited by 225
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Kang, Y. M., Giugliano, R. P., Ran, X., Deedwania, P., De Ferrari, G. M., George, J. T., Gouni-Berthold, I., Paiva da Silva Lima, G., Handelsman, Y., Lewis, B. S., et al. (2025) · Diabetes Care · doi:10.2337/dc25-0942 · Cited by 9
Self-citationNicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Franco, D. R., Kahn, S. E., Lincoff, A. M., Martins, R. F., McGuire, D. K., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag452
Self-citation
Metadata
- Authors
- Lee, M. M. Y., Ghouri, N., Misra, A., Kang, Y. M., Rutter, M. K., Gerstein, H. C., McGuire, D. K., & Sattar, N.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2025-02-20
- Volume
- 48
- Issue
- 3
- Pages
- 489-493
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4407787676
- Cited by
- 92
- References
- 9
- FWCI
- 19.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- British Heart Foundation Centre of Research (RE/18/6/34217)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.